Full history for every metric is available with a Kvantra account
Haemato AG (HAEK.DE)
Key financial summary
Financials in EUR| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 289 | 274 | 198 | 238 | 285 | 248 | 261 |
| Operating profit | €m | 8 | 9 | |||||
| Net profit | €m | 7 | 6 | -1 | -5 | 7 | 8 | 10 |
| EPS reported | € | 1.57 | 1.85 | |||||
| Operating cashflow per share | € | 3.84 | 3.84 | |||||
| Capex per share | € | 0.21 | 0.21 | |||||
| FCF per share | € | 3.64 | 3.64 | |||||
| Free cash flow | €m | 19 | 10 | |||||
| Net debt | €m | -21 | -13 | |||||
| Book value equity | €m | 147 | 149 | |||||
| Book value per share | € | 28.25 | 28.68 | |||||
| Number of shares | m | 5.21 | 5.21 | |||||
| DPS (TTM paid) | € | 1.10 | 1.20 |
Financial summary
Financials in EUR| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | 10.45 | - | |||||
| P/B LTM | x | 0.58 | 0.75 | |||||
| P/S LTM | x | 0.34 | 0.43 | |||||
| P/FCF LTM | x | 4.51 | 10.64 | |||||
| EV/EBITDA LTM | x | 5.49 | 11.51 | |||||
| EV/Sales LTM | x | 0.27 | 0.38 | |||||
| Earnings Yield LTM | % | 9.57% | 7.35% | |||||
| FCF Yield | % | 22.17% | 9.39% | |||||
| Quality | ||||||||
| ROE | % | 5.57% | 5.61% | |||||
| ROIC | % | 4.25% | 4.25% | |||||
| Operating margin | % | 3.34% | 3.34% | |||||
| Gross margin | % | 6.17% | 6.17% | |||||
| FCF/Sales | % | 7.63% | 7.63% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | +25.60% | +2427.3% | |||||
| Sales Growth YoY | % | -12.95% | +2.48% | |||||
| Net Income Growth YoY | % | +25.39% | +2578.0% | |||||
| FCF Growth | % | +40.29% | -55.72% | |||||
| Operating Profit Growth | % | -25.68% | +10.19% | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 6.73% | 5.61% | |||||
| Dividend Growth | % | +10.00% | - | |||||
| Payout Ratio | % | 70.19% | 70.19% | |||||
| FCF/Debt | x | 3.54 | 3.39 | |||||
| Net Debt/EBITDA | x | -1.51 | -1.51 | |||||
| EBIT/Net interest | x | 23.14 | 23.14 | |||||
| Net debt/market cap | % | -24.72% | -11.96% | |||||
| Net debt/Equity | x | -0.14 | -0.09 | |||||
| Gross debt/equity | x | 0.04 | 0.02 | |||||
Company overview
HAEMATO AG is a German pharmaceutical company with a varied operational scope. It is engaged in both the importation and distribution of European-sourced medicinal products and medical supplies. Additionally, the company develops and markets its own line of generic pharmaceuticals. Its product offerings span critical therapeutic areas such as oncology, HIV treatment, rheumatology, neurological disorders, and cardiovascular health. HAEMATO also provides products tailored for aesthetic medicine and general cosmetic applications. Expanding its footprint, the firm develops and commercializes specialized medical devices and technology solutions for aesthetic surgery and cosmetic dermatology. Its clientele is diverse, serving pharmaceutical wholesalers, pharmacies, physicians, hospitals, and medical laboratories. Founded in 1993, HAEMATO AG is headquartered in Schönefeld, Germany.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Haemato AG (HAEK.DE)
HAEMATO AG is a German pharmaceutical company with a varied operational scope. It is engaged in both the importation and distribution of European-sourced medicinal products and medical supplies. Additionally, the company develops and markets its own line of generic pharmaceuticals. Its product offerings span critical therapeutic areas such as oncology, HIV treatment, rheumatology, neurological disorders, and cardiovascular health. HAEMATO also provides products tailored for aesthetic medicine and general cosmetic applications. Expanding its footprint, the firm develops and commercializes specialized medical devices and technology solutions for aesthetic surgery and cosmetic dermatology. Its clientele is diverse, serving pharmaceutical wholesalers, pharmacies, physicians, hospitals, and medical laboratories. Founded in 1993, HAEMATO AG is headquartered in Schönefeld, Germany.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free